Literature DB >> 26056811

Experiences in surgery of primary malignant brain tumours in the primary sensori-motor cortex practical recommendations and results of a single institution.

Susan Noell1, Guenther C Feigl2, Georgios Naros1, Susanne Barking1, Marcos Tatagiba1, Rainer Ritz3.   

Abstract

OBJECTIVE: Tumour resection in the Rolandic region is a challenge. Aim of this study is to review a series of patients malignant glioma surgery in the Rolandic region which was performed by combinations of neuronavigation, sonography, 5-aminolevulinic acid fluorescence guided (5-ALA) surgery and intraoperative electrophysiological monitoring (IOM).
METHODS: 29 patients suffering malignant gliomas in the motor cortex (17) and sensory cortex (12) were analyzed with respect to functional outcome and grade of resections.
RESULTS: Improvement of motor function was seen in 41.5% one week after surgery, 41.5% were stable, only 17% deteriorated. After three months patients had an improvement of motor function in 56%, of Karnofsky Score (KPS) 27% and sensory function was improved in 8%. Deterioration of motor function was seen in 16%, in sensory function 4% and in KPS 28% after three months. 25% showed no residual tumour in early post surgical contrast enhanced MRI. 10% had less than 2% residual tumour and 15% had 2-5% residual tumour.
CONCLUSIONS: Preoperative functional neuroimaging, neuronavigation for planning the surgical approach and resection margins, intraoperative sonography and 5-ALA guided surgery in combination with the application of IOM shows that functional outcome and total to subtotal resection of malignant glioma in the Rolandic region is feasible.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  5-ALA; Brain tumour surgery; Glioblastoma; Intraoperative monitoring; Rolandic region

Mesh:

Year:  2015        PMID: 26056811     DOI: 10.1016/j.clineuro.2015.05.021

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  6 in total

1.  Functional outcomes, extent of resection, and bright/vague fluorescence interface in resection of glioblastomas involving the motor pathways assisted by 5-ALA.

Authors:  Giovanni Muscas; Simone Orlandini; Camilla Bonaudo; Maddalena Dardo; Alice Esposito; Luca Campagnaro; Riccardo Carrai; Enrico Fainardi; Pietro Ciccarino; Alessandro Della Puppa
Journal:  Acta Neurochir (Wien)       Date:  2022-09-10       Impact factor: 2.816

Review 2.  Various shades of red-a systematic analysis of qualitative estimation of ALA-derived fluorescence in neurosurgery.

Authors:  Marcel A Kamp; Zarela Krause Molle; Christopher Munoz-Bendix; Marion Rapp; Michael Sabel; Hans-Jakob Steiger; Jan F Cornelius
Journal:  Neurosurg Rev       Date:  2016-05-25       Impact factor: 3.042

3.  Acute changes in diffusion tensor-derived metrics and its correlation with the motor outcome in gliomas adjacent to the corticospinal tract.

Authors:  Santiago Cepeda; Sergio García-García; Ignacio Arrese; María Velasco-Casares; Rosario Sarabia
Journal:  Surg Neurol Int       Date:  2021-02-10

Review 4.  Agents for fluorescence-guided glioma surgery: a systematic review of preclinical and clinical results.

Authors:  Joeky T Senders; Ivo S Muskens; Rosalie Schnoor; Aditya V Karhade; David J Cote; Timothy R Smith; Marike L D Broekman
Journal:  Acta Neurochir (Wien)       Date:  2016-11-22       Impact factor: 2.216

Review 5.  Rethinking the standard trans-cortical approaches in the light of superficial white matter anatomy.

Authors:  Francesco Latini; Mats Ryttlefors
Journal:  Neural Regen Res       Date:  2015-12       Impact factor: 5.135

6.  Image and motor behavior for monitoring tumor growth in C6 glioma model.

Authors:  Taylla Klei Felix Souza; Mariana Penteado Nucci; Javier Bustamante Mamani; Helio Rodrigues da Silva; Daianne Maciely Carvalho Fantacini; Lucas Eduardo Botelho de Souza; Virginia Picanço-Castro; Dimas Tadeu Covas; Edson Luis Vidoto; Alberto Tannús; Lionel Fernel Gamarra
Journal:  PLoS One       Date:  2018-07-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.